We are live on ! Find out more
SFM

Sphera Funds Management Portfolio holdings

AUM $630M
1-Year Est. Return 108.65%
This Fund
S&P 500
This Quarter Est. Return
-12.3%
1 Year Est. Return
+108.65%
3 Year Est. Return
+217.64%
5 Year Est. Return
+342.91%
10 Year Est. Return
+2,254.45%
AUM
$784M
AUM Growth
-$237M
Cap. Flow
-$75.7M
Cap. Flow %
-9.66%
Top 10 Hldgs %
46.1%
Holding
163
New
33
Increased
30
Reduced
43
Closed
36

Top Buys

Rank Stock Value
1
TEVA icon
Teva Pharmaceuticals
TEVA
+$37.3M
2
INCY icon
Incyte
INCY
+$11.2M
3
BMRN icon
BioMarin Pharmaceuticals
BMRN
+$8.68M
4
SHPG
Shire pic
SHPG
+$8.32M
5
BIIB icon
Biogen
BIIB
+$8.01M

Top Sells

Rank Stock Value
1
MRK icon
Merck
MRK
+$22.8M
2
GILD icon
Gilead Sciences
GILD
+$22.2M
3
PFE icon
Pfizer
PFE
+$10.1M
4
CXRX
Concordia International Corp. Common Stock
CXRX
+$9.03M
5
VRNT
Verint Systems
VRNT
+$8.47M

Sector Composition

Rank Sector Weight
1 Healthcare 55.74%
2 Industrials 4.06%
3 Utilities 2.54%
4 Technology 1.27%
5 Consumer Discretionary 0.92%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
NDRM
101
DELISTED
NeuroDerm Ltd. Ordinary Shares
NDRM
$1.76M 0.22%
+85,000
New +$1.74M
PANW icon
102
Palo Alto Networks
PANW
$270B
$1.72M 0.22%
+60,012
New +$1.77M
NBRV
103
DELISTED
Nabriva Therapeutics plc Ordinary Shares Ireland
NBRV
$1.66M 0.21%
+700
New +$1.86M
PVLA
104
Palvella Therapeutics
PVLA
$1.99B
$1.65M 0.21%
11,250
-3,750
-25% -$837K
ZGNX
105
DELISTED
Zogenix, Inc.
ZGNX
$1.62M 0.21%
+120,000
New +$2.16M
ARRY
106
DELISTED
Array Biopharma Inc
ARRY
$1.6M 0.2%
350,000
-450,000
-56% -$2.67M
OCRX
107
DELISTED
Ocera Therapeutics, Inc.
OCRX
$1.58M 0.2%
+500,000
New +$1.92M
ALDX icon
108
Aldeyra Therapeutics
ALDX
$92.9M
$1.54M 0.2%
265,000
– –
KALV
109
DELISTED
KalVista Pharmaceuticals
KALV
$1.43M 0.18%
28,571
– –
MRNS
110
DELISTED
Marinus Pharmaceuticals, Inc
MRNS
$1.35M 0.17%
40,530
-34,103
-46% -$1.92M
TBRA
111
DELISTED
Tobira Therapeutics, Inc. Common Stock
TBRA
$1.33M 0.17%
137,622
– –
LRMR icon
112
Larimar Therapeutics
LRMR
$397M
$1.28M 0.16%
+3,333
New +$1.5M
CLCD
113
DELISTED
CoLucid Pharmaceuticals, Inc.
CLCD
$1.23M 0.16%
317,250
– –
HRTX icon
114
Heron Therapeutics
HRTX
$93.9M
$1.22M 0.16%
+50,000
New +$1.67M
ORBK
115
DELISTED
Orbotech Ltd
ORBK
$1.21M 0.15%
78,482
-136,440
-63% -$2.38M
ANAC
116
DELISTED
ANACOR PHARMACEUTICALS INC COM
ANAC
$1.18M 0.15%
+10,000
New +$1.31M
NVAX icon
117
Novavax
NVAX
$1.2B
$1.06M 0.14%
+7,500
New +$1.68M
AXTA icon
118
Axalta
AXTA
$7.66B
$1.03M 0.13%
+40,626
New +$1.21M
WIX icon
119
WIX.com
WIX
$2.3B
$1.01M 0.13%
58,160
-62,145
-52% -$1.39M
GNVC
120
DELISTED
GenVec, Inc.
GNVC
$832K 0.11%
36,033
– –
CHTR icon
121
Charter Communications
CHTR
$17.3B
$708K 0.09%
4,026
-6,039
-60% -$1.1M
APTV icon
122
Aptiv
APTV
$12B
$696K 0.09%
9,150
-43,920
-83% -$3.38M
AOS icon
123
A.O. Smith
AOS
$8.17B
$681K 0.09%
20,882
-80,358
-79% -$2.75M
SAGE
124
DELISTED
Sage Therapeutics
SAGE
$339K 0.04%
8,000
-40,000
-83% -$2.47M
NICE icon
125
Nice
NICE
$5.79B
$255K 0.03%
4,525
-13,725
-75% -$857K
3 4
5
6 7

Similar funds

VIM
Vancity Investment Management Vancouver, British Columbia, Canada $629M AUM 2.49% 1-Year Est. Return
KCMH
Keywise Capital Management (HK) Hong Kong $630M AUM 81.01% 1-Year Est. Return
FCFC
First Commonwealth Financial Corp Indiana, Pennsylvania $629M AUM 20.47% 1-Year Est. Return
BI
BlueSpruce Investments Chicago, Illinois $631M AUM 11.83% 1-Year Est. Return
PWW
Pettyjohn Wood & White Lynchburg, Virginia $628M AUM 20.96% 1-Year Est. Return
TTSTC
Texas Treasury Safekeeping Trust Company Austin, Texas $628M AUM 15.58% 1-Year Est. Return
SWP
Summit Wealth Partners Orlando, Florida $632M AUM 9.71% 1-Year Est. Return
EIM
Essex Investment Management Boston, Massachusetts $632M AUM 95.36% 1-Year Est. Return

Sphera Funds Management's Q3 2015 Portfolio in Review

As of Q3 2015, Sphera Funds Management held 163 positions worth $784M, down 23% from $1.02B the previous quarter. Its ten largest holdings account for 46% of the portfolio.

Sphera Funds Management withdrew a net $75.7M in Q3 2015, closing 36 positions and reducing 43 holdings. Its most notable exit was Merck, an estimated $22.8M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 56% of assets, up from 51% a quarter earlier, followed by Industrials and Utilities.

Against the trend, Sphera Funds Management opened a new position in Incyte worth $11M.

  • Sphera Funds Management's largest Q3 2015 buy was Incyte: 100,000 shares worth $11M.
  • Sphera Funds Management added most to Teva Pharmaceuticals in Q3 2015, an estimated $37.3M increase.
  • Sphera Funds Management's biggest Q3 2015 reduction was Gilead Sciences, cutting an estimated $22.2M.
  • Sphera Funds Management fully exited Merck in Q3 2015, selling an estimated $22.8M.
  • Sphera Funds Management's ten largest holdings make up 46% of its $784M portfolio in Q3 2015.
  • Sphera Funds Management opened 33 new positions and closed 36 in Q3 2015.
  • Sphera Funds Management's portfolio value fell 23% quarter-over-quarter to $784M.

Based on Sphera Funds Management's 13F filing for Q3 2015, filed 16 Nov 2015.